Literature DB >> 2931490

Immunoprophylaxis of infection with hepatitis B virus in infants born to hepatitis B surface antigen-positive carrier mothers.

K J Lo, Y T Tsai, S D Lee, T C Wu, J Y Wang, G H Chen, C L Yeh, B N Chiang, S H Yeh, A Goudeau.   

Abstract

Infants born to carrier mothers positive for hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg) received 5 micrograms of hepatitis B virus (HBV) vaccine on four occasions. Group 1 received vaccine only, group 2 received vaccine plus hepatitis B immune globulin (HBIG) at birth, and group 3 received vaccine plus HBIG at birth and at one month. Infants born to HBeAg-positive mothers (group 4) received a reduced dose of vaccine (2.5 micrograms) on three occasions as well as HBIG at birth. As compared with 78.4% of the control group (infants whose parents refused vaccination) who became chronic HBV carriers at the age of 14 months, the protective efficacy rate of vaccination was 75.3% in group 1,85.5% in group 2,89.7% in group 3, and 87.2% in group 4. HBV vaccine (5 micrograms) was also given to infants born to HBsAg-positive, HBeAg-negative mothers on four on four occasions. The antibody response to HBsAg in vaccine recipients was 12% after the first dose, 44% after the second dose, and 75% and 100% at six months and 1.5 years of age, respectively.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2931490     DOI: 10.1093/infdis/152.4.817

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  17 in total

Review 1.  Treatment of chronic hepatitis B: new antiviral therapies.

Authors:  F Yao; R G Gish
Journal:  Curr Gastroenterol Rep       Date:  1999 Feb-Mar

2.  Long-term hepatitis B vaccine in infants born to hepatitis B e antigen positive mothers.

Authors:  Y Poovorawan; S Sanpavat; S Chumdermpadetsuk; A Safary
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1997-07       Impact factor: 5.747

Review 3.  Screening for hepatocellular carcinoma. Review and perspective.

Authors:  J C Ellis
Journal:  West J Med       Date:  1988-08

Review 4.  Primary hepatocellular carcinoma following perinatal transmission of hepatitis B.

Authors:  M J Tong; S Govindarajan
Journal:  West J Med       Date:  1988-02

Review 5.  Update on diagnosis, management, and prevention of hepatitis B virus infection.

Authors:  F J Mahoney
Journal:  Clin Microbiol Rev       Date:  1999-04       Impact factor: 26.132

6.  Randomised controlled trial of lymphoblastoid interferon alfa in Europid men with chronic hepatitis B virus infection.

Authors:  M G Brook; G Chan; I Yap; P Karayiannis; A M Lever; M Jacyna; J Main; H C Thomas
Journal:  BMJ       Date:  1989-09-09

7.  Hepatitis C virus infection is a risk factor for tumor recurrence after resection of small hepatocellular carcinomas.

Authors:  Teh-Ia Huo; Jaw-Ching Wu; Cheng-Yuan Hsia; Gar-Yang Chau; Wing-Yiu Lui; Yi-Hsiang Huang; Pui-Ching Lee; Full-Young Chang; Shou-Dong Lee
Journal:  World J Surg       Date:  2004-08-03       Impact factor: 3.352

Review 8.  Hepatitis B virus: where do we stand and what is the next step for eradication?

Authors:  Haruki Komatsu
Journal:  World J Gastroenterol       Date:  2014-07-21       Impact factor: 5.742

9.  Antenatal survey for the seroprevalence of HTLV-1 infections in the West Midlands, England.

Authors:  S Nightingale; D Orton; D Ratcliffe; S Skidmore; J Tosswill; U Desselberger
Journal:  Epidemiol Infect       Date:  1993-04       Impact factor: 2.451

10.  HBV perinatal transmission.

Authors:  Muhammad Umar; Shifa Umar; Haider Ali Khan
Journal:  Int J Hepatol       Date:  2013-04-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.